Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marillion Pharmaceuticals and Cytokine PharmaSciences or CPSI have entered into a license agreement granting Marillion exclusive worldwide rights to develop and commercialize CPSI's Pilobuc buccal insert for the treatment of xerostomia.
Subscribe to our email newsletter
CPSI’s Pilobuc insert is based on a hydrogel polymer technology that delivers drugs to the buccal mucosa. Pilobuc allows for the sustained buccal delivery of pilocarpine while reducing the side effects associated with oral systemic treatments.
Zahed Subhan, CEO of Marillion Pharmaceuticals, said: “Pilobuc is a novel, proprietary, buccal formulation of pilocarpine shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.”